Anti-Human SELP Recombinant Antibody(Crizanlizumab)
-
产品编号
YR1442
-
别名
科研级 Crizanlizumab ( 立赞利珠单抗 ), Anti-SELP Recombinant Antibody, Research Grade Crizanlizumab
-
规格
- 1mg
- 5mg
Alias | 科研级 Crizanlizumab ( 立赞利珠单抗 ), Anti-SELP Recombinant Antibody, Research Grade Crizanlizumab |
Catalog Number | YR1442 |
Molecular Name | Crizanlizumab |
Size | 1mg, 5mg |
Clonity | Monoclonal |
Purity | >95% as determined by SDS-PAGE |
Concentration | 1mg/ml |
Antibody Isotype | IgG2 Kappa |
Formulation | PBS, pH7.5 |
Background | Crizanlizumab, sold under the brand name Adakveo, is a monoclonal antibody medication developed by Novartis targeted towards P-selectin. It was announced by the company as an effective drug to prevent vaso-occlusive crisis in patients with sickle cell anemia. The result of the Phase II SUSTAIN clinical trial was published in December 2016. |
CAS Number | 1690318-25-2 |
Application | ELISA, IHC, IF, IP, FCM, FuncS |
Storage Condition | It is recommended to aliquote and store at -20°C for long term storage. Avoid repeated freezing and thawing cycles. |
Remarks | This product is for research use only. |
Shipping Condition | Shipped on ice packs. |
Target | SELP[Homo sapiens] |